

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

RWPE-1

RRID:CVCL_3791

Type: Cell Line

Proper Citation

CLS Cat# 305217, RRID:CVCL_3791

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3791

Proper Citation: CLS Cat# 305217, RRID:CVCL_3791

Description: Cell line RWPE-1 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:8977636](#), [PMID:9214605](#), [PMID:9214606](#), [PMID:20215515](#), [PMID:22275356](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:30305041](#), [PMID:30787054](#)

Comments: Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: RWPE-1

Synonyms: RWPE1

Cross References: BTO:BTO_0003709, CLO:CLO_0008905, EFO:EFO_0002323, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-3610, ATCC:CRL-3607, ATCC:CRL-11609, BCRJ:0389, BioSample:SAMN03470832, BioSample:SAMN05292437, BioSample:SAMN07709991, BioSample:SAMN07709992, BioSample:SAMN07709993, BioSample:SAMN07709994, BioSample:SAMN07709995, BioSample:SAMN07709996, BioSample:SAMN07709997, cancercellines:CVCL_3791, CCRID:3101HUMGNHu37, CCRID:3101HUMSCSP5025, CCRID:4201HUM-CCTCC00178, CCTCC:GDC0178, Cell_Model_Passport:SIDM00020, ChEMBL-Cells:ChEMBL4295468, ChEMBL-Targets:ChEMBL4296492, CLS:305217, EGA:EGAS00001000978, ENCODE:ENCBS124FCL, ENCODE:ENCBS192LWI, ENCODE:ENCBS263AAA,

ENCODE:ENCBS875FPF, GEO:GSM827387, GEO:GSM1008595, GEO:GSM1374860, GEO:GSM1670396, IGRhCellID:RWPE1, Lonza:870, Pharmacodb:RWPE1_1336_2019, Progenetix:CVCL_3791, PubChem_Cell_line:CVCL_3791, Wikidata:Q54951497

ID: CVCL_3791

Vendor: CLS

Catalog Number: 305217

Record Creation Time: 20250130T072729+0000

Record Last Update: 20260905T184140+0000

Ratings and Alerts

No rating or validation information has been found for RWPE-1.

No alerts have been found for RWPE-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 738 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Fu H, et al. (2026) A smart gene circuit for precise regulation of tumor cell behavior. Synthetic and systems biotechnology, 11, 237.

Macke AJ, et al. (2026) Dynamic Shifts in ER-Plasma Membrane Junctions Signaling Define Pro-Metastatic N-Glycosylation and Predict Prostate Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(30), e22885.

Yang J, et al. (2026) Astragaloside IV directly targets PPP1R14B to sensitize prostate cancer to anti-PD-1 immunotherapy by remodeling the CX3CL1/CD8+ T cell axis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158158.

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. EMBO molecular medicine, 18(5), 1967.

Yang M, et al. (2026) MCCC2 stabilizes LTBP1 via suppressing SMURF1-dependent ubiquitination to drive bone metastasis in prostate cancer. Oncogene, 45(28), 2779.

Shi W, et al. (2026) Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer. Cancer & metabolism, 14(1).

- Liu SS, et al. (2026) Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1. *Acta pharmacologica Sinica*, 47(6), 1643.
- Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. *iScience*, 29(7), 116409.
- Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. *Cancer gene therapy*.
- Zhang H, et al. (2026) ROS Cascade-Amplified Polymeric Nanosystem Exhibiting Multi-Pathway Induction of Immunogenic Cell Death and Chemotherapeutic Efficacy in Tumor. *Advanced healthcare materials*, 15(25), e71279.
- Zheng W, et al. (2026) hsa-circKLK3-25 promotes epithelial-mesenchymal transition and malignant progression of prostate cancer through the JNK/ERK signaling pathway. *American journal of cancer research*, 16(3), 1081.
- Kim YN, et al. (2026) Phytochemical Profiling of the Halophyte *Artemisia fukudo* Makino and Its In Vitro Effects on Androgen-Related Pathways Associated With Benign Prostatic Hyperplasia and Alopecia. *ChemistryOpen*, 15(3), e202500481.
- Sekar A, et al. (2026) TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. *EMBO molecular medicine*, 18(6), 2062.
- Bernard MJ, et al. (2026) OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance. *Molecular cancer research : MCR*, 24(5), 356.
- Luo T, et al. (2026) Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer. *Advanced healthcare materials*, e71387.
- Alaimo A, et al. (2025) TRPM8 levels determine tumor vulnerability to channel agonists. *Molecular oncology*.
- Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. *npj biological physics and mechanics*, 2(1), 19.
- Diao Y, et al. (2025) A novel biochip-based liquid biopsy for extracellular vesicle RNA detection in prostate cancer. *Cancer biology & therapy*, 26(1), 2593744.
- Dathathri E, et al. (2025) PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer Patients. *Cancer research communications*, 5(8), 1359.
- Zhang Y, et al. (2025) Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*, 12(29), e04192.